Harousseau Jean-Luc
Centre Hospitalier Universitaire Hôtel-Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1157-74, x. doi: 10.1016/j.hoc.2007.08.001.
Hematopoietic stem cell transplantation (SCT) was introduced in the treatment of multiple myeloma in the 1980s. In the autologous setting, the use of peripheral blood stem cells instead of bone marrow has markedly improved feasibility. In fit patients who have normal renal function and are younger than 65 years of age, randomized studies have shown the superiority of autologous stem cell transplantation (ASCT) compared with conventional chemotherapy. ASCT is now considered the standard of care in this population of patients. It is currently challenged, however, by the introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide. The role of allogenic SCT remains controversial, even with reduced intensity conditionings. Prospective studies still are needed to evaluate the impact of both autologous and allogeneic SCT in this new era.
造血干细胞移植（SCT）于20世纪80年代被引入用于治疗多发性骨髓瘤。在自体移植中，使用外周血干细胞而非骨髓显著提高了可行性。在肾功能正常且年龄小于65岁的合适患者中，随机研究表明自体干细胞移植（ASCT）优于传统化疗。ASCT现在被认为是这类患者的标准治疗方法。然而，目前它正受到沙利度胺、硼替佐米和来那度胺等新型药物的挑战。异基因SCT的作用仍存在争议，即使是采用降低强度的预处理方案。在这个新时代，仍需要前瞻性研究来评估自体和异基因SCT的影响。
